Astrana Health, Inc. Reports Third Quarter 2026 Results

Astrana Health reported Q3 2026 revenue of $1,023.6 million, up 7% year over year, and adjusted EBITDA of $77.2 million, up 13%; net income attributable to Astrana rose to $13.0 million from $0.4 million. For the first nine months, revenue increased 33% to $2,961.2 million and adjusted EBITDA rose 39% to $212.4 million, while operating cash flow was $117.1 million and free cash flow was $105.4 million. The company narrowed 2026 guidance to revenue of $3.9–$4.0 billion, adjusted EBITDA of $261–$274 million, and free cash flow of $107.5–$130 million; it also cited a Georgia practice acquisition and new client and Medicare Advantage partnerships.

Analysis

The headline earnings growth overstates the clean acceleration: the quarter’s adjusted EPS growth was modest, while GAAP net income is amplified by an unusually low prior-year base. More important is whether the stronger adjusted EBITDA margin is repeatable or reflects mix and timing; Q4 guidance implies a substantial sequential step-down from Q3 EBITDA, making the call’s explanation of utilization, medical-cost trends, and seasonality the near-term price catalyst. In a capitated model, membership growth can add scale but also magnifies exposure to medical-cost inflation and adverse utilization. New payer relationships and the Georgia acquisition are therefore only positive if incremental members retain acceptable risk-adjusted economics; onboarding and integration execution matter more than client announcements.

Cash conversion is a notable counterweight: operating cash flow was roughly flat year over year over nine months despite materially higher earnings, while receivables and medical liabilities both expanded. Verify aging/collectability and the timing of payer settlements before underwriting the reported FCF guidance. Gross debt remains material relative to the cash balance, and rising year-to-date interest expense can constrain equity-value conversion even if operating growth continues. Separately, the disclosed material weakness in internal controls raises reporting and execution risk; track remediation in the next filing. Consolidated VIE assets should not be treated as freely available parent liquidity.

Immediate catalyst is management’s call and next-session interpretation of the Q4 run rate. Over 1–3 months, monitor payer onboarding, receivable collections, and medical-cost commentary. Over 6–18 months, successful provider-platform adoption could improve operating leverage, but reimbursement changes, utilization surprises, or acquisition integration failures could reverse the thesis. Contrarian view: the market may focus on the dramatic GAAP rebound, while the key signal is modest quarterly adjusted-EPS growth plus weaker guided Q4 EBITDA. Without valuation and market-reaction data, this supports confirmation rather than chasing.

Key Decisions for Investors

• Do not chase ASTH solely on the GAAP earnings rebound. Reassess after the call for a quantified bridge explaining the Q3-to-Q4 adjusted EBITDA decline and the durability of margin improvement.
• Keep ASTH on a conditional long watchlist, not an unconditional entry: consider a starter only if management supports guidance with stable medical-cost/utilization trends and evidence that new payer memberships are economically attractive. No price target is warranted from the supplied data.
• Track quarterly receivables aging, cash from operations versus adjusted earnings, medical liabilities, and debt/interest costs. A deterioration in collections or a guidance cut to adjusted EBITDA/FCF would falsify the operating-leverage thesis.
• Treat the material-weakness remediation and restricted availability of VIE assets as explicit risk controls; do not equate consolidated cash flows or assets with unrestricted parent-company liquidity.